Dyne Therapeutics, Inc.
DYN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $97,219 | $99,236 | $106,447 | $81,805 |
| G&A Expenses | $16,673 | $16,555 | $15,925 | $15,303 |
| SG&A Expenses | $16,673 | $16,555 | $15,925 | $15,303 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $113,892 | $115,791 | $122,372 | $97,108 |
| Operating Income | -$113,892 | -$115,791 | -$122,372 | -$97,108 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5,851 | $4,934 | $7,011 | $7,566 |
| Pre-Tax Income | -$108,041 | -$110,857 | -$115,361 | -$89,542 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$108,041 | -$110,857 | -$115,361 | -$89,542 |
| % Margin | – | – | – | – |
| EPS | -0.76 | -0.97 | -1.05 | -0.88 |
| % Growth | 21.6% | 7.6% | -19.3% | – |
| EPS Diluted | -0.76 | -0.97 | -1.05 | -0.88 |
| Weighted Avg Shares Out | 141,811 | 113,873 | 109,912 | 101,982 |
| Weighted Avg Shares Out Dil | 141,811 | 113,873 | 109,912 | 101,982 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,476 | $6,625 | $7,100 | $7,592 |
| Interest Expense | $2,904 | $94 | $0 | $0 |
| Depreciation & Amortization | $523 | $503 | $502 | $450 |
| EBITDA | -$104,614 | -$110,260 | -$121,870 | -$96,658 |
| % Margin | – | – | – | – |